Sign in
TerminatedNo phase

How Gas-Filled Intragastric Balloons or Endoscopic Sleeve Gastroplasty Affect Hunger, Hunger Hormones, and Gastric Emptying Compared to Meal Replacements

Key facts

Who runs it
University of Colorado, Denver
Where
Aurora, United StatesSee the site
Trial code
Status
Terminated
People taking part
3 people enrolled
Started
2 Mar 2020
Ended
22 Feb 2024
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • GF-IGB: Obalon Balloon
  • Medically Supervised Meal Replacement Program: My New Weigh
  • Endoscopic sleeve gastroplasty: (ESG)
Record updated
2 June 2026
Why it stopped
The Principal Investigator left the University of Colorado

Who can take part

Age
22 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Male and female participants aged 22-65
  • Weight Stable (<5% weight change in the last 3 months)
  • Initiating treatment with GF-IGB, ESG, or medically supervised MRP
  • BMI of 30-40

Who cannot take part

  • Use of weight loss medications in the past 3 months
  • History of liver disease
  • History of uncontrolled thyroid disease
  • History of anemia
  • History of diabetes
  • History of eating disorder
  • History of uncontrolled depression defined as a score of ≥ 10 on PHQ-9 (Patient Health Questionnaire-9)
  • History of gastroparesis
  • History of bariatric surgery
  • History to allergy or intolerance to any component of the meal used in the gastric emptying study or mixed meal test
  • Women who are pregnant or lactating
  • Currently incarcerated
  • Non English speaking
  • Decisionally challenged adults

Where in United States

  • University of ColoradoAurora, United States

About the trial

What the trial wants to find out

The disease obesity continues to be a major health issue in the US with over one third of the population having a mass index >30 kg/m2. Obesity is associated with serious cardiometabolic complications including diabetes, hypertension, dyslipidemia and myocardial infarction. Rates of successful obesity treatment with weight loss and weight maintenance remain low. Several endoscopic bariatric therapies and procedures have been approved for use in the United States, including three intragastric balloon systems (2 fluid-filled and one gas-filled) and endoscopic sleeve gastroplasty (ESG), both of which have lower risks than bariatric surgery and do not alter gastrointestinal anatomy. Weight loss with all intragastric balloons and ESG is higher than lifestyle therapy or weight loss medications, but less than bariatric surgery. Unlike weight loss medications where weight loss from the medication is regained within 6-8 months after therapy ends, weight loss maintenance with intragastric balloons remains high with 66-88.5% of the weight loss maintained 6 months after device removal. Data suggests that space occupying devices with a volume of 400 ml or more in the stomach increase feelings of fullness and result in weight loss, but this does not explain the prolonged effect of weight loss maintenance after balloon removal. Although few studies have investigated the mechanism of action of fluid-filled balloons and one study with 4 patients undergoing ESG on weight loss, these data suggest that gastric emptying as well as space occupation contribute to weight loss. However, no studies have investigated the mechanisms of action of gas filled intragastric balloons on weight loss.

Read full original descriptionShow less

Understanding the mechanisms responsible for weight loss with the gas filled intragastric balloon system and ESG as well as any weight loss independent effects on blood glucose control would lay the groundwork for studies evaluating predictors of response to improve patient selection as well as studies understanding the mechanisms behind weight loss maintenance and developing strategies to prolong weight loss maintenance.

Therefore, the purpose of this pilot study is to determine the effects 10% total body weight loss (%TBWL) in patients with obesity treated with the intragastric balloon (GF- IGB) system or ESG compared to patients with obesity treated with a meal replacement program (MRP) on 1) gastric emptying, 2) hormonal adaptation to weight loss and 3) hunger.

The 3 groups in the trial

  • GF-IGB: Obalon BalloonExisting treatment, for comparison

    Obalon balloons are gas-filled balloons used for weight loss by taking up more space in the stomach. There are three separate balloons that are placed. They are inflated once the capsules containing the balloons are swallowed. The second balloon is swallowed two weeks after the first balloon, and the third balloon is swallowed four to eight weeks after the second balloon. All three balloons are removed six months after the first balloon is placed.

  • Medically Supervised Meal Replacement Program: My New WeighExisting treatment, for comparison

    Meal Replacements are used for weight loss in order to achieve a very low-calorie diet that is nutritionally balanced. Four to five meal replacements are consumed per day. If only four meal replacements are consumed per day, three servings of vegetables and two servings of fruit are consumed as well. This program lasts for about five months or twenty weeks.

  • Endoscopic Sleeve Gastroplasty: ESGExisting treatment, for comparison

    Endoscopic sleeve gastroplasty (ESG) is a weight loss procedure that uses an endoscopic suturing device known as Overstitch to reduce the size of the stomach. This decreases the amount of food one can consume, which leads to the consumption of fewer calories throughout the day, resulting in weight loss.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effect of a Gas-filled Intragastric Balloon or Endoscopic Sleeve Gastroplasty for Weight Loss Compared With a Meal Replacement Weight Loss Program on Gastric Emptying, Hormonal Adaptation to Weight Loss, and Hunger
Record updated
2 June 2026